X

Drug Profile

Trientine - Merck/Tsumura/Bausch Health Companies

Alternative Names: Cuprid; Metalite; MK 681; Syprine; Tecza; Teta; TJA 250; Trien; Triestine

Latest Information Update: 24 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Tsumura
Developer Bausch Health Companies; Merck & Co; Tsumura; Waymade Australia Pty Ltd
Class Ethylenediamines; Small molecules
Mechanism of Action Chelating agents

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Marketed Hepatolenticular degeneration

Most Recent Events

11 Jan 2021 Registered for Hepatolenticular degeneration in Australia (PO)
13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
03 Mar 2014 Valeant and Kadmon Pharmaceuticals agree to co-promote Syprine^® in USA for Wilson's disease

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com